MapLight to discuss future of autism drug with FDA despite Phase 2 disappointment

MapLight plans other meet with the FDA after its autism drug ML-004 missed its Phase 2 primary endpoint on social communication but improved irritability in teenagers.

Raccontata daendpoints.news